On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to evaluate seven peptide-related bulk drug substances for potential inclusion on the 503A Bulks List. For patients and providers following the compounded peptide updates, this meeting is a significant moment in an ongoing regulatory process.
What Was Reviewed?
The committee evaluated the following substances and their nominated clinical uses:
- BPC-157: Ulcerative colitis
- KPV: Wound healing and inflammatory conditions
- TB-500: Wound healing
- MOTS-c: Obesity and osteoporosis
- Emideltide (DSIP): Opioid withdrawal, chronic insomnia, and narcolepsy
- Semax: Cerebral ischemia, migraine, and trigeminal neuralgia
- Epitalon: Insomnia
What Does This Mean for Patients and Providers?
The 503A Bulks List determines which bulk drug substances licensed compounding pharmacies can legally use to prepare patient-specific medications. If a substance is added to the list, compounding pharmacies can prepare it under a valid prescription. If it is not added, access through compounding becomes significantly more restricted.
The committee's recommendations are advisory. The FDA will review them alongside the full evidence record and make its own final determination, a process that typically takes several months.
What Should You Do Now?
If you are a patient currently using a compounded preparation that includes any of these substances, do not make changes to your treatment plan based on this update. Stay in contact with your prescribing provider and monitor official FDA communications as the process moves forward.
If you are a provider with questions about how these regulatory developments affect your patients, we welcome that conversation.
We Are Here to Help You Navigate This
The regulatory landscape around compounded peptides has been evolving for several years, and we know it can be difficult to track. At The Compounding Lab, we follow these developments closely and are committed to operating within the legal framework as it continues to develop.
If you have questions about where a specific peptide stands or what options may be available to your patients, reach out to our team directly. Call us at (937) 723-2885 or visit us at 7415 Old Troy Pike in Huber Heights. We are happy to talk through it with you.
For full meeting details and FDA briefing documents, visit the official PCAC meeting page at fda.gov.
Note: This post is for informational purposes only and reflects publicly available FDA meeting materials as of July 2026. It does not constitute medical or legal advice and should not be used as the basis for any treatment decisions.